Compare S&P500 ETF (SPY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs TransMedics Group Inc — how do they compare? S&P500 ETF trades at $763.01, while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: S&P500 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPY | TMDX | |
|---|---|---|
52-Week High | $777.82 | $150.42 |
52-Week Low | $631.99 | $61.99 |
Market Cap | — | $3.00B |
Sector | — | Technology |
Enterprise Value | — | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF) trades at $766.00, down 0.55% with neutral technical signals. The ETF shows mixed sentiment amid geopolitical tensions and AI-driven market concentration risks. Recent news highlights S&P 500 resilience despite oil price surges and Fed rate concerns, with strategists targeting 8,000 levels. A dividend of $1.90 is scheduled for July 2026.
Outlook remains cautiously optimistic with potential for further gains driven by AI productivity and earnings growth, though elevated valuations and Middle East tensions pose near-term volatility risks. Long-term investors may find value in market exposure despite current highs.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
